• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sientra Announces Departure of CFO and Appointment of Interim CFO

    3/11/21 4:01:00 PM ET
    $SIEN
    Industrial Specialties
    Health Care
    Get the next $SIEN alert in real time by email

    SANTA BARBARA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that Paul Little is stepping down from his position as Chief Financial Officer, Senior Vice President and Treasurer, to pursue other opportunities effective March 12, 2021. Valerie Miller, current Vice President, Corporate Controller, will serve as interim Chief Financial Officer effective upon Mr. Little’s resignation as the Company completes its search for a permanent replacement.

    “We thank Paul for his diligent work and greatly appreciate all his contributions to our team through his tenure at Sientra,” said Ron Menezes, President and Chief Executive Officer of Sientra. “He was integral in positioning our company for durable future growth by strengthening our balance sheet and driving efficiencies to accelerate our path to revenue growth and we wish him well in his future endeavors.”

    “It has been a privilege to work alongside the entire Sientra team and to have been a part of the company’s growth story,” said Mr. Little. “While stepping down was a difficult decision, and one based solely on personal reasons, I am confident that Sientra will remain on a solid path forward under Ron’s leadership.”

    Mr. Menezes added, "Given her strong knowledge of our business and financial reporting standards I have great confidence in Ms. Miller’s ability to lead the finance team on an interim basis as we recruit a new Chief Financial Officer. We expect that the transition will have no material impact on our operations, and we remain confident in our near-term growth prospects as we remain well capitalized with a highly efficient team."

    Ms. Miller joined Sientra in September 2017 as Vice President, Corporate Controller and has since been responsible for the accounting and finance functions of the Company. Prior to joining Sientra, Ms. Miller served as Corporate Controller at The Trade Desk, Inc. and as Senior Director of Finance & Accounting at LinkedIn. Previously, she served as a Vice President on the finance team of Mentor Worldwide, a subsidiary of Johnson & Johnson. Ms. Miller holds a Bachelor’s in Economics from the University of California, Santa Barbara.

    Mr. Little’s departure is not related to any disagreement with the company’s accounting principles or practices or financial statement disclosures.

    About Sientra

    Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company uniquely focused on plastic surgeons. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM® the #1 performing, preferred and recommended scar gel of plastic surgeons(*). The Company’s miraDry Segment, comprised of its miraDry® system, is approved for sale in over 56 international markets and is the only non-surgical, FDA-cleared device indicated for the permanent reduction of underarm sweat and hair and may also reduce odor.

    Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.

    (*) Data on file

    Forward-Looking Statements

    This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding the CFO transition and employment matters related thereto and the Company’s growth prospects. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Sientra disclaims any obligation to update these forward-looking statements.

    Contact
    Investor Relations
    805-679-8885


    Get the next $SIEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SIEN

    DatePrice TargetRatingAnalyst
    4/14/2022$8.00Buy
    Lake Street
    More analyst ratings

    $SIEN
    Financials

    Live finance-specific insights

    See more
    • Sientra Reports Third Quarter Financial and Operational Results

      IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022

      11/9/23 4:05:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook

      IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023. Total unaudited revenue for the third quarter of 2023 is expected to be in the range of $19.2 million to $19.7 million, compared to total revenue of $22.6 million in the prior year period. Third quarter results were adversely affected by overall softness in the market as well as more pronounced seasonal headwinds that led to a reduced number of augmentation and reconstru

      10/30/23 5:00:51 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Record Second Quarter Financial and Operational Results

      Revenue growth of 7.5% driven by continued market share gains in reconstruction and augmentation Best operational results in company history with 95% and 63% year-over-year improvement inoperating cash flow and adjusted EBITDA respectively Continued success in advancing products through the FDA regulatory process with clearance of Allox2 Pro™, the first and only FDA-cleared MRI-compatible tissue expander IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the second quarter tha

      8/10/23 4:03:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Menezes Ronald covered exercise/tax liability with 3,625 shares, decreasing direct ownership by 18% to 16,775 units (SEC Form 4)

      4 - Sientra, Inc. (0001551693) (Issuer)

      11/14/23 3:50:38 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Van Hove Caroline F. covered exercise/tax liability with 741 shares, decreasing direct ownership by 8% to 8,239 units (SEC Form 4)

      4 - Sientra, Inc. (0001551693) (Issuer)

      11/14/23 3:50:11 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form 4: Bennett Oliver Christian was granted 2,739 shares, increasing direct ownership by 13% to 23,100 units

      4 - Sientra, Inc. (0001551693) (Issuer)

      9/11/23 9:05:47 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction

      Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra's breast reconstruction and augmentation business Nuance Intermediary, LLC is the successful bidder for substantially all of the assets used in Sientra's BIOCORNEUM scar treatment business IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. ("Sientra" or the "Company") announced that, following the completion of its Section 363 sales auction, Tiger Aesthetics Medical, LLC ("Tiger") has been declared the successful bidder for certain of the assets of Sientra used in its breast reconstruction and augmentation business. As consideration for the acquisition, Tiger will pay a cash consid

      4/2/24 6:30:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

      IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing and commercializing safe and innovative solutions for the best aesthetic outcomes, announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on February 12, 2024. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. The Company seeks to execute an expedited sale process. Sientra will utilize existing cash reserves and $22.5 million in new money d

      2/13/24 8:30:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Third Quarter Financial and Operational Results

      IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022

      11/9/23 4:05:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Sientra Announces Appointment of Alexander W. Casdin to Board of Directors

      IRVINE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced the appointment of Alexander W. Casdin to the Company's Board of Directors, effective June 15, 2023. "On the heels of no less than 3 new product approvals in the United States in the past 12 months, and with continued strong topline performance and a near-term path to profitability, we are delighted to welcome Alex to the Sientra Board of Directors," said Caro Van Hove, Executive Chair of Sientra. "With Kevin O'Boyle retiring from the Board after nearly a decade of exceptional

      6/20/23 8:35:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Appoints Two Medical Aesthetics Leaders to its Board of Directors

      SANTA BARBARA, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced the appointment of Dr. Irina Erenburg and Nori Ebersole to its Board of Directors effective July 16, 2021. "We are extremely pleased to welcome Irina and Nori to the Sientra Board," said Caroline Van Hove, Executive Chairwoman of Sientra. "Irina and Nori's deep respective experiences and competencies in building disruptive R&D engines and best-in-class organizations in Medical Aesthetics will significantly contribute to Sientra's high-growth strategy and our singular focus to be the number one

      7/19/21 8:00:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Announces Appointment of Chief Financial Officer

      SANTA BARBARA, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced that Andy Schmidt has been appointed Chief Financial Officer (CFO) effective immediately. As a key member of Sientra's executive leadership team, Mr. Schmidt will lead the Company's financial operations. "We are extremely pleased to welcome a strong leader like Andy to the Sientra team. His experience with growth-oriented public companies will be invaluable as we work towards expanding our market share and advancing the art of plastic surgery," said Ron Menezes, President and Chief Executive Of

      7/12/21 8:00:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Sientra with a new price target

      Lake Street initiated coverage of Sientra with a rating of Buy and set a new price target of $8.00

      4/14/22 9:15:44 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Canaccord Genuity reiterated coverage on Sientra with a new price target

      Canaccord Genuity reiterated coverage of Sientra with a rating of Buy and set a new price target of $10.00 from $9.00 previously

      5/12/21 11:21:33 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SVB Leerink reiterated coverage on Sientra with a new price target

      SVB Leerink reiterated coverage of Sientra with a rating of Outperform and set a new price target of $11.00 from $10.00 previously

      5/12/21 7:20:27 AM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    SEC Filings

    See more
    • Sientra Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      2/16/24 4:15:47 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      2/13/24 9:00:40 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      1/29/24 6:07:11 AM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Sientra Inc. (Amendment)

      SC 13G/A - Sientra, Inc. (0001551693) (Subject)

      2/20/24 1:38:37 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Sientra Inc.

      SC 13G - Sientra, Inc. (0001551693) (Subject)

      2/6/24 10:00:53 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Sientra Inc.

      SC 13G - Sientra, Inc. (0001551693) (Subject)

      2/15/23 3:19:14 PM ET
      $SIEN
      Industrial Specialties
      Health Care